Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2021 07:00 ET | Source: MediWound Ltd.

MediWound to Participate in Upcoming Investor Conferences in January

YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
December 21, 2020 07:30 ET | Source: MediWound Ltd.

Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent

YAVNE, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
December 14, 2020 16:15 ET | Source: MediWound Ltd.

MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
November 10, 2020 07:00 ET | Source: MediWound Ltd.

MediWound Reports Third Quarter 2020 Financial Results

Total Third Quarter Revenues of $6.6 Million Increased 29% Year-over-Year Assigned PDUFA Goal Date of June 29, 2021 for NexoBrid BLA YAVNE, Israel, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MediWound...
November 02, 2020 16:01 ET | Source: MediWound Ltd.

MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020

YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
October 28, 2020 07:00 ET | Source: MediWound Ltd.

MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study

YAVNE, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
October 14, 2020 08:00 ET | Source: MediWound Ltd.

MediWound Studying the Effect of EscharEx on Biofilm Burden

YAVNE, Israel, Oct. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) ("MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in...
September 16, 2020 07:30 ET | Source: MediWound Ltd.

MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs...
September 03, 2020 09:00 ET | Source: MediWound Ltd.

MediWound to Present at Upcoming Investor Conferences in September

YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in...
August 25, 2020 07:00 ET | Source: MediWound Ltd.

MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness

YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the...